Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics of taxane/platinum therapy in ovarian cancer.

International journal of gynecological cancer : official journal of the International Gynecological Cancer Society - 1 Dec 2009

Marsh Sharon

Abstract excerpt

OBJECTIVES: Taxane (paclitaxel or docetaxel) and platinum (cisplatin or carboplatin) chemotherapy is commonly used in the treatment of ovarian cancer. Despite an initial high response to therapy, the 5-year survival rate remains low. The identification of pharmacogenomic markers to identify patie...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Combined Chemotherapy Protocols
Share to Biomarkers, Pharmacological
Share to Carcinoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Gene Expression Regulation, Neoplastic

Share to Ovarian Neoplasms

Share to Pharmacogenetics

Share to Platinum Compounds

Share to Taxoids

Source

Identifiers

PMID: 19955911
DOI: 10.1111/IGC.0b013e3181c10513

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 2 Sept 2026. Prepared record publication-19955911-2026-09-02.2. Manifest publication-graph-cohort-2026-09-02.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 2 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics of taxane/platinum therapy in ovarian cancer.PMID 19955911Read ↗

Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.Semantic proximity Read ↗

Genetic markers for prediction of treatment outcomes in ovarian cancer.Semantic proximity Read ↗

Genetic polymorphisms and the efficacy and toxicity of cisplatin-based chemotherapy in ovarian cancer patientsSemantic proximity Read ↗

Pharmacogenomic assessment of cisplatin-based chemotherapy outcomes in ovarian cancer.Semantic proximity Read ↗

‘Genetic profiling’ and ovarian cancer therapy (Review)Semantic proximity Read ↗

Using pharmacogene polymorphism panels to detect germline pharmacodynamic markers in oncology.Semantic proximity Read ↗

Can pharmacogenetics explain efficacy and safety of cisplatin pharmacotherapy?Semantic proximity Read ↗

Pharmacogenomics in cancer therapy: is host genome variability important?Semantic proximity Read ↗

Genetic variability in drug transport, metabolism or DNA repair affecting toxicity of chemotherapy in ovarian cancer.Semantic proximity Read ↗

Pharmacogenomics of Cisplatin-Based Chemotherapy in Ovarian Cancer Patients of Different Ethnic OriginsSemantic proximity Read ↗

Genomic profiling of platinum-resistant ovarian cancer: The road into druggable targetsSemantic proximity Read ↗

Copy number polymorphisms and anticancer pharmacogenomics.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.